Sodium zirconium cyclosilicate is under clinical development by AstraZeneca and currently in Phase III for Chronic Kidney Disease (Chronic Renal Failure). According to GlobalData, Phase III drugs for Chronic Kidney Disease (Chronic Renal Failure) have a 62% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Sodium zirconium cyclosilicate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Sodium zirconium cyclosilicate overview
Sodium zirconium cyclosilicate (Lokelma) is a selective oral sorbent. It is formulated as powder for suspension for oral route of administration. Lokelma is indicated for the treatment of hyperkalaemia in adults and chronic kidney disease.
Sodium zirconium cyclosilicate (Lokelma) was under development for the treatment of chronic kidney disease, hyperkalemia in Australia, South Korea, and Taiwan. The drug candidate is a non-systemic sorbent which is developed based on ZrSi technology platform.
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of Sodium zirconium cyclosilicate’s drug-specific PTSR and LoA scores, buy the report here.